News & Updates
Filter by Specialty:
Antireflux mucosectomy effective against treatment-refractory GERD
Patients with treatment-refractory gastroesophageal reflux disease (GERD) may find relief from antireflux mucosectomy (ARMS), suggests a study.
Antireflux mucosectomy effective against treatment-refractory GERD
01 Jun 2022Compromised nutritional, immunological status ups infection risk after gastric cancer surgery
Infection is a common complication in gastric cancer stage II/III patients after gastrectomy, a recent study has found. A low prognostic nutritional index score seems to be an important risk factor for such an outcome.
Compromised nutritional, immunological status ups infection risk after gastric cancer surgery
27 May 2022GI symptoms in T1D linked to microvascular complications
A recent study has demonstrated the importance of gastrointestinal (GI) symptoms as a clinical morbidity and that these symptoms are associated with increasing age, duration of type 1 diabetes (T1D), haemoglobin A1c (HbA1c), and microvascular complications, but not with autoimmune comorbidities including coeliac disease (CD).
GI symptoms in T1D linked to microvascular complications
25 May 2022Symptoms of anxiety, depression higher in ulcerative colitis
Ulcerative colitis patients suffer from higher levels of anxiety and depressive symptoms, a recent study has found. In addition, disease activity seems to be a good predictor of the severity of these symptoms.
Symptoms of anxiety, depression higher in ulcerative colitis
21 May 2022Infliximab does not contribute to long-term weight gain in IBD patients
Treatment with infliximab does not lead to a general long-term weight gain in patients with inflammatory bowel disease (IBD), claims a study.
Infliximab does not contribute to long-term weight gain in IBD patients
20 May 2022Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.